Press Releases

March 11 2014

BIO commended the Centers for Medicare & Medicaid Services (CMS) for announcing their...

March 6 2012

BIO applauded the House Energy and Commerce Committee’s passage of the Medicare...

April 19 2011

Democratic and Republican party leaders and strategists will share their differing...

February 9 2011

BIO announces that former Senator John B. Breaux (D-LA), former Member, Senate Finance...

January 6 2011

BIO releases a report by Health Advances on the limitations of the nation’s...

January 3 2011

The 2011 BIO International Convention will highlight the latest trends and the newest...

May 4 2010

A new report issued by the Biotechnology Industry Organization underscores how biotechnology...

April 12 2007

S. 3 Would Weaken Medicare Part D Drug Benefit

February 26 2007

Private Sector Negotiations for Medicare Part D Provide Savings and Access to Innovative...

November 25 2003

Carl B. Feldbaum, president of the Biotechnology Industry Organization (BIO), today issued the...

November 12 1998

Carl B Feldbaum, president of  BIO, today issued the following statement on the need for...

February 11 1998

Carl B. Feldbaum, president of BIO today issued the following statement after the Senate voted...

January 7 1998

Carl B. Feldbaum, president of BIO, today issued the following statement in response to news...

June 7 1997

Carl B. Feldbaum, president of BIO, issued the following statement today in response to the...

October 1 2014
The Biotechnology Industry Organization (BIO) appreciates the opportunity to comment on the Centers for Medicare & Medicaid Services' (CMS) proposed rule regarding payment policies under the physician fee schedule (PFS) and other revisions to Part B for calendar year (CY) 2011 (the "Proposed Rule").
September 2 2014
The Biotechnology Industry Organization (BIO) appreciates the opportunity to comment on the proposed changes to the Medicare Evidence Development and Coverage Advisory Committee’s (MEDCAC’s) charter, which were released on August 1, 2014.
September 2 2014
The Biotechnology Industry Organization (BIO) appreciates the opportunity to comment on the Centers for Medicare & Medicaid Services’ (CMS’s) proposed rule regarding payment policies under the End-Stage Renal Disease Prospective Payment published in the Federal Register on July 11, 2014 (the “Proposed Rule”).
September 2 2014
The Biotechnology Industry Organization (BIO) appreciates this opportunity to comment on the Centers for Medicare & Medicaid Services’ (CMS’s) proposed rule regarding payment policies under the physician fee schedule (PFS), clinical laboratory fee schedule, and other revisions to Part B for calendar year (CY) 2015 (the “Proposed Rule”).
September 2 2014
The Biotechnology Industry Organization (BIO) is pleased to comment on the Centers for Medicare & Medicaid Services (CMS) proposed rule regarding payment policies under the calendar year (CY) 2015 hospital outpatient prospective payment system (OPPS), published in the Federal Register on July 14, 2014 (the "Proposed Rule").
May 29 2014
Many participating hospitals appear to be deviating from the program’s original intent by leveraging 340B discounts for financial gain, rather than improving patient access
March 11 2014
BIO commended the Centers for Medicare & Medicaid Services (CMS) for announcing their decision to halt movement on several proposals in their Medicare Part D draft rule.
March 6 2012
BIO applauded the House Energy and Commerce Committee’s passage of the Medicare Decisions Accountability Act, H.R. 452, which would repeal the Independent Payment Advisory Board (IPAB) established in the health care reform law.
April 19 2011
Democratic and Republican party leaders and strategists will share their differing perspectives in a keynote panel, titled "The Future of Healthcare Reform," during a Keynote Luncheon at the 2011 BIO International Convention.
February 9 2011
BIO announces that former Senator John B. Breaux (D-LA), former Member, Senate Finance Committee, along with former Congressman Jim McCrery III (R-LA), former Ranking Member, House Ways & Means Committee, will be panelists at the 13th Annual BIO CEO & Investor Conference.